A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs ABI-H0731 (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Proof of concept; Therapeutic Use
- Sponsors Assembly Biosciences
- 11 Nov 2019 Results presented in an Assembly Biosciences Media Release.
- 11 Nov 2019 According to an Assembly Biosciences media release, data were presented at AASLD 2019.
- 07 Nov 2019 According to an Assembly Biosciences media release, data from this trial to be presented at AASLD on November 11, 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History